Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial)-Reference-Cited by-同舟云学术

Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial)

Published:2020-04 Issue: Volume:305 Page:11-17
ISSN:0167-5273
Container-title:International Journal of Cardiology
language:en
Short-container-title:International Journal of Cardiology

Author:

Jin Cai De,Kim Moo Hyun,Guo Long Zhe,Jin Enze,Shin Eun-Seok,Ann Soe Hee,Cho Young-Rak,Park Jong Sung,Kim Soo Jin,Lee Michael S.

Funder

National Research Foundation of Korea

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference42 articles.

1. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines;Amsterdam;J. Am. Coll. Cardiol.,2014

3. Viewpoint: “underutilisation of novel antiplatelet agents--myths, generics, and economics”;Serebruany;Thromb. Haemost.,2014

4. Genetic determinants of response to clopidogrel and cardiovascular events;Simon;N. Engl. J. Med.,2009

5. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis;Mega;JAMA,2010

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association;Circulation;2024-08-06

2. Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis;European Heart Journal - Cardiovascular Pharmacotherapy;2024-05-16

3. Differences in Optimal Platelet Reactivity after Potent P2Y12 Inhibitor Treatment in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention;Journal of Clinical Medicine;2022-04-28

4. Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial;Journal of Clinical Medicine;2021-06-18

5. Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy;Cardiovascular Intervention and Therapeutics;2021-04-04